文献速递胸部肿瘤

STK11功能突变与非小细胞肺癌度伐利尤单抗及联合替西木单抗耐药相关且可被STAT3敲低逆转

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
PubMed 文献 · Cancer Discov · 2021-07-06

本研究在三个I/II期试验的非鳞非小细胞肺癌患者中评估STK11突变与PD-1/PD-L1阻断疗效的关系。STK11突变与度伐利尤单抗(单药或联合替西木单抗)耐药相关,且不依赖KRAS突变状态;患者肿瘤及外周呈现中性粒细胞、Th17及免疫检查点相关标志物表达升高的独特免疫表型。临床前模型中反义寡核苷酸降低STAT3可逆转免疫治疗耐药。

要点

  • STK11突变与非鳞NSCLC对度伐利尤单抗(单药或联合替西木单抗)耐药相关,且独立于KRAS突变状态。
  • STK11突变患者肿瘤中CXCL2、IL6、IL17A及免疫检查点标志物表达升高,外周亦见相关变化。
  • 临床前STK11敲除模型中反义寡核苷酸降低STAT3可逆转免疫治疗耐药。

核心结论

  • STK11突变与非鳞NSCLC患者对度伐利尤单抗(单药或联合替西木单抗)耐药相关,且独立于KRAS突变状态。
  • STK11突变可能通过抑制性髓系细胞生物学等机制阻碍检查点阻断应答,STAT3靶向治疗或可逆转。

研究设计与样本

  • 研究纳入三个I/II期试验中的非鳞非小细胞肺癌患者,评估STK11突变与PD-1/PD-L1阻断疗效的关联。
  • 采用肿瘤组织、全血和血清的回顾性评估分析STK11突变患者的免疫表型。
  • 临床前采用STK11敲除模型及反义寡核苷酸降低STAT3验证逆转耐药。

主要发现

  • STK11突变与度伐利尤单抗(单药或联合替西木单抗)耐药相关,且独立于KRAS突变状态。
  • STK11突变患者肿瘤中中性粒细胞相关标志物(CXCL2、IL6)、Th17相关标志物(IL17A)及免疫检查点表达升高。
  • 外周血和血清中观察到与肿瘤微环境相关的免疫表型变化。
  • 临床前STK11敲除模型中反义寡核苷酸降低STAT3可逆转免疫治疗耐药。

临床怎么用

  • STK11突变状态或可辅助识别非鳞NSCLC中对度伐利尤单抗(单药或联合替西木单抗)应答可能性较低的患者。
  • STK11突变非鳞NSCLC患者肿瘤中STAT3信号相关基因和细胞因子表达升高,提示STAT3靶向药物可作为免疫治疗联合候选。

局限性

  • 研究基于三个I/II期试验的回顾性评估,样本量及前瞻性验证未在摘要中报告。
  • STAT3逆转耐药的结果来自临床前模型,尚未在患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non-small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associated with resistance to the anti-PD-L1 antibody durvalumab (alone/with the anti-CTLA4 antibody tremelimumab) independently of KRAS mutational status, highlighting STK11 as a potential driver of resistance to checkpoint blockade. Retrospective assessments of tumor tissue, whole blood, and serum revealed a unique immune phenotype in patients with STK11 mutations, with increased expression of markers associated with neutrophils (i.e., CXCL2, IL6), Th17 contexture (i.e., IL17A), and immune checkpoints. Associated changes were observed in the periphery. Reduction of STAT3 in the tumor microenvironment using an antisense oligonucleotide reversed immunotherapy resistance in preclinical STK11 knockout models. These results suggest that STK11 mutations may hinder response to checkpoint blockade through mechanisms including suppressive myeloid cell biology, which could be reversed by STAT3-targeted therapy. SIGNIFICANCE: Patients with nonsquamous STK11-mutant (STK11mut) NSCLC are less likely than STK11 wild-type (STK11wt) patients to respond to anti-PD-L1 ± anti-CTLA4 immunotherapies, and their tumors show increased expression of genes and cytokines that activate STAT3 signaling. Preclinically, STAT3 modulation reverses this resistance, suggesting STAT3-targeted agents as potential combination partners for immunotherapies in STK11mut NSCLC.This article is highlighted in the In This Issue feature, p. 2659.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Pore N, Wu S, Standifer N, et al. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. Cancer Discov. 2021. PMID: 34230008. doi:10.1158/2159-8290.CD-20-1543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。